X
Merck, Pfizer covering bases with SGLT2 inhibitor latecomer
https://pharmaphorum.com/news/merck-pfizer-cover-bases-sglt2-inhibitor/
Merck
ASCO 2017: Breast cancer next target for Keytruda
May 18, 2017Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.
The cancer challenge: the quest for a cure is only half the battle
May 18, 2017The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
Trump demands cuts to ‘astronomical’ drug prices – but pharma reassured
February 1, 2017Trump calls pharma leaders to White House to discuss cutting taxes, regulations – and drug prices
Cancer market commentary: Roche’s Tecentriq muscles into NSCLC
October 10, 2016Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Eye on ESMO: Day Three – Merck & Co. wins big lung cancer battle
October 9, 2016Merck unveils impressive data on Keytruda, trumping BMS’ Opdivo
Eye on ESMO: Day 1 – Access in spotlight before data deluge
October 8, 2016Europe’s biggest cancer conference ESMO is underway
Merck makes its move: Keytruda filed for first line lung cancer
September 7, 2016Merck steals a march on rival BMS.
Merck, Pfizer and Gilead all interested in Medivation buy-out
August 19, 2016Sanofi has competition in its bid to acquire cancer specialist
1 2
